CLINICAL AND MOLECULAR ASPECTS OF MUCINOUS OVARIAN TUMORS: ETIOPATHOGENESIS, INDIVIDUALIZATION OF TREATMENT
- Authors: Kedrova AG1, Levakov SA1, Shablovskiy OR1, Vanke NS1, Nechaeva OV1, Maksimenko TA1
-
Affiliations:
- ФГУЗ КБ № 83 ФМБА России
- Issue: Vol 1, No 3 (2010)
- Pages: 21-31
- Section: Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/8163
- DOI: https://doi.org/10.17816/clinpract1321-31
- ID: 8163
Cite item
Full Text
Abstract
About the authors
A G Kedrova
ФГУЗ КБ № 83 ФМБА России
S A Levakov
ФГУЗ КБ № 83 ФМБА России
O R Shablovskiy
ФГУЗ КБ № 83 ФМБА России
N S Vanke
ФГУЗ КБ № 83 ФМБА России
O V Nechaeva
ФГУЗ КБ № 83 ФМБА России
T A Maksimenko
ФГУЗ КБ № 83 ФМБА России
References
- Teramukai S., K. Ochiai, H. Tada, et.al. A new prognostic index of advanced epithelial ovarian cancer (PIEPOC): A JMTO OC01-01 study // ASCО 2006, abs. 5061.
- Pecorelli et.al. Staging Classification and clinical practice Guidelines for Gynacological Cancer. A collaboration between FIGO and IGCS 2006, Kuala Lumpur, FIGO.
- Чекалова М.А., Шабанов М.А., Поддубная И.В., Горелова И.А. Ультразвуковая диагностика муцинозных новообразований яичников // Ультразвуковая и функциональная диагностика. 2006. № 2. С. 39-47.
- Liu P., Moon J., Alberts D.S. et al. A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy // ASCO 2006, abs.5080.
- Tanabe H., Katsumata N., Matsumoto K. et.al. CA125 nadir as a prognostic factor in advanced ovarian carcinoma: A retrospective study of 84 patients achieving clinical CR // ASCO 2006, Abs. 5007.
- Nadal R.M. , B. M. Ojeda, V. Artigas, et.al. Stratification of the normal range of CA125 after chemotherapy as a predictive factor in carcinoma of the ovary // ASCO 2006, abs. 5059.
- Aabo K., Adams M., Adnitt P. et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group // Br. J. Cancer. 1998; 78: 1479-87.
- Berek J.S., Bertelsen K., du Bois A. et al. Epithelial ovarian cancer: 1998 consensus statements. // Ann. Oncol. 1999. 10 Suppl 1: 87-92.
- Hoskins W.J. Surgical staging and cytoreductive surgery of epithelial ovarian cancer // Cancer. 1993;71: 1534-1540.
- Горелова И.А.// Муцинозные опухоли яичников различного потенциала злокачественности. Автореф. на соиск. степ. канд. мед. наук. 2008. Москва.
- Yamao K., Yanagisawa A., Takahashi K. Clinicopathological Features and Prognosis of Mucinous Cystic Neoplasm With Ovarian-Type Stroma: A Multi-Institutional Study of the Japan Pancreas Society // Pancreas. 2010 Sep 29.
- Schmuck R.B., Pietzner K., Buckendahl A. Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report // Anticancer Res. 2010. Jul; 30(7):2991-4.
- Piver S.M. Optimal surgical therapy in stage I-II ovarian malignecies // Int. J. Radiat Oncol. Biol. Phys. 1982; 8: 247-249.
- Landoni F., A. Maggioni, T. Dell'anna et.al. Randomized trial of systematic lymphadenectomy (LY) vs nodal sampling (SA) at second look surgery (SLS) in ovarian cancer patients: Final results. // ASCO 2006, Abs.5068.
- Young R.C., Brady M.F. Randomized Clinical Trial of adjuvant treatment of women with early (FIGO I-IIa high risk) ovarian cancer - GOG Proc. // ASCO 1999 :18: 357a.
- Bagley C.M., Young R.S., Schein P.S. Ovarian carcinoma metastatic to the diaphragm - frequently undiagnosed at laparotomy // Am. J. Obstet Gynecol. 1973, 116: 397-400.
- Харитонова Т.П., Поддубная И.В., Мартынова Ж.А. и соавт. Оптимизация лечения распространенного рака яичников // Врач. 2008. № 8. С. 35-36.
- Tang L., Yang J., Ng S.K., Rodriguez N. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer // Eur. J. Cancer. 2010 Jan;46(1):170-9.
- Heinzelmann-Schwarz V.A., Gardiner-Garden M., Henshall S.M. A distinct molecular profile associated with mucinous epithelial ovarian cancer // Br. J. of Cancer. 2006. 94, 904-913.
- Bolis G., Colombo N., Pecorelli S. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatmant or chonic phosphate (32P) G.I.C.O.G. // Ann. Oncol. 1995: 6 : 887-93.
- Wamunyokoli F.W., Bnome J.Y., Lee C.M. Expression profiling of mucinous tumor of theovary indentify genes of clinic-pathologic impotance // Clin. Cancer Res. 2006, 12(3P). P. 690-700.
- Nomura Kouichi, Shigeo Aizawa, Hiroshi Hano. Ovarian mucinous border-line tumors of intestinal type without intraepithelial carcinoma: Are they still tumors of low malignant potential? // Pathology International, June 2004, Vol. 54, Issue 6. P. 420-24.
- Kolomainen D.F., A'Hern R., Coxon F.Y. et. al. Can patients with relapsed, previously untreated, stage i epithelial ovarian cancer be successfully treated with salvage therapy? // J. Clin. Oncol. 2003. Vol. 21, Issue 16: 3113-18.
- Lee J.H., Zhang X., Shin B.K., Lee E.S. Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study // J. Pathology. 2009;41(3):229-33.